

Clinical Policy: Pretomanid

Reference Number: CP.PMN.222

Effective Date: 03.01.20

Last Review Date: 02.25

Line of Business: Commercial, HIM, Medicaid

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

Description

Pretomanid is a nitroimidazooxazine antimycobacterial drug.

FDA Approved Indication(s)

Limited population: Pretomanid is indicated, as part of a combination regimen with bedaquiline and linezolid for the treatment of adults with pulmonary tuberculosis (TB) that is resistant to isoniazid, rifamycins, a fluoroquinolone and a second line injectable antibacterial drug OR adults with pulmonary TB resistant to isoniazid and rifampin, who are treatment-intolerant or nonresponsive to standard therapy. Approval of this indication is based on limited clinical safety and efficacy data. This drug is indicated for use in a limited and specific population of patients.

Limitation(s) of use:

- Pretomanid tablets are not indicated in patients with:
 - Drug-sensitive (DS) TB
 - Latent infection due to *Mycobacterium tuberculosis*
 - Extra-pulmonary infection due to *Mycobacterium tuberculosis*
 - TB resistant to isoniazid and rifampin who are responsive to standard therapy and not treatment-intolerant
 - TB with known resistance to any component of the combination
- Safety and effectiveness of pretomanid has not been established for its use in combination with drugs other than bedaquiline and linezolid as part of the recommended dosing regimen.

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation® that pretomanid is **medically necessary** when the following criteria are met:

I. Initial Approval Criteria**A. Drug Resistant Tuberculosis (must meet all):**

1. Diagnosis of pulmonary TB;
2. Documentation of one of the following (a or b):
 - a. Resistance to isoniazid and rifampin, and member is treatment-intolerant or nonresponsive to standard therapy (*see Appendix D*);
 - b. Resistance to isoniazid, rifamycins, a fluoroquinolone, and a second line injectable antibacterial drug (e.g., amikacin, capreomycin, kanamycin);

3. Prescribed by or in consultation with an expert in the treatment of tuberculosis (e.g., state or county public health department, specialists affiliated with TB Centers of Excellence as designated by the CDC, infectious disease specialists managing TB clinics);
4. Age ≥ 15 years;
5. Prescribed in combination with Sirturo[®] (bedaquiline) and linezolid;
**Prior authorization may be required for Sirturo and linezolid.*
6. One of the following (a or b):
 - a. Prescribed in combination with moxifloxacin (off-label);
 - b. Documented resistance to fluoroquinolones, unless contraindicated or clinically significant adverse effects are experienced;
7. Dose does not exceed 200 mg (1 tablet) per day.

Approval duration: 26 weeks

B. Other diagnoses/indications (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
 - a. For drugs on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.33 for health insurance marketplace, and CP.PMN.255 for Medicaid; or
 - b. For drugs NOT on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.103 for health insurance marketplace, and CP.PMN.16 for Medicaid; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid.

II. Continued Therapy

A. Drug Resistant Tuberculosis (must meet all):

1. Member meets one of the following (a or b):
 - a. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
 - b. Member is currently receiving medication and is enrolled in a state and product with continuity of care regulations (*refer to state specific addendums for CC.PHARM.03A and CC.PHARM.03B*);
2. Member is responding positively to therapy;
3. Member meets one of the following (a or b):
 - a. Member continues to receive Sirturo and linezolid in combination with pretomanid;
 - b. Member continues to receive Sirturo and has completed at least 4 weeks of linezolid therapy;

4. If request is for treatment beyond 26 weeks, provider attestation of delayed treatment response within the first 8 weeks as assessed by time to culture conversion, persistent culture positivity, clinical response to treatment, and other underlying clinical factors, or modified based on adverse events;
5. If request is for a dose increase, new dose does not exceed 200 mg (1 tablet) per day.

Approval duration: up to a total treatment duration of 26 weeks (9 months if evidence of delayed culture conversion)

B. Other diagnoses/indications (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
 - a. For drugs on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.33 for health insurance marketplace, and CP.PMN.255 for Medicaid; or
 - b. For drugs NOT on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.103 for health insurance marketplace, and CP.PMN.16 for Medicaid; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid.

III. Diagnoses/Indications for which coverage is NOT authorized:

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid, or evidence of coverage documents.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

BPaL: bedaquiline, pretomanid, and linezolid

CDC: Centers for Disease Control

FDA: Food and Drug Administration

Appendix B: Therapeutic Alternatives

This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
pyrazinamide	Follow weight-based dosing in prescribing information	4,000 mg/dose

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
cycloserine	10 to 15 mg/kg PO QD or BID	1,000 mg/day
ethionamide	10 to 20 mg/kg PO QD or BID	1,000 mg/day
streptomycin	15 mg/kg IM or IV QD or 25 mg/kg PO 3 times weekly	20 mg/kg/day
amikacin/kanamycin	15 mg/kg IM or IV QD or 25 mg/kg PO 3 times weekly	15 mg/kg/day
capreomycin	15 mg/kg IM or IV QD or 25 mg/kg PO 3 times weekly	1,000 mg/day
para-amino salicylic acid	8 to 12 g PO BID to TID	12 g/day
levofloxacin	500 to 1,000 mg PO or IV QD	1,000 mg/day
moxifloxacin	400 mg PO or IV QD	400 mg/day
linezolid (Zyvox [®])	600 - 1,200 mg PO QD	1,200 mg/day
Sirturo [®] (bedaquiline)	400 mg PO QD for the first 2 weeks, followed by 200 mg PO three times per week for remaining 24 weeks.	400 mg/day

Therapeutic alternatives are listed as Brand name[®] (generic) when the drug is available by brand name only and generic (Brand name[®]) when the drug is available by both brand and generic.

Appendix C: Contraindications/Boxed Warnings

- Contraindication(s): patients who have contraindications to Sirturo and/or linezolid
- Boxed warning(s): none reported

Appendix D: General Information

- CDC Centers of Excellence for TB: https://www.cdc.gov/tb/education/tb_coe/default.htm
- Standard pulmonary TB therapy consists of 4-month rifapentine-moxifloxacin regimen or 6- or 9- month RIPE (rifamycin, isoniazid, pyrazinamide, and ethambutol) regimen.
- Pretomanid should only be used in combination with Sirturo and linezolid.
- Dosing of the combination regimen of pretomanid, Sirturo, and linezolid can be extended beyond 26 weeks if necessary, to a maximum of 9 months, in patients with delayed culture conversion.
 - Delayed culture conversion: two consecutive negative sputum cultures following an initial positive culture.
- Laboratory confirmation of multi-drug resistant TB must show TB with an isolate showing genotypic or phenotypic resistance to isoniazid and rifampin.
- Laboratory confirmation of extensively drug resistant TB must show TB with an isolate showing genotypic or phenotypic resistance to isoniazid, rifampin, fluoroquinolones, as well as second-line injectable agents such as aminoglycosides or capreomycin.
- Linezolid starting dose of 1,200 mg daily for 26 weeks may be managed as follows:
 - Adjusted to 600 mg daily and further reduced to 300 mg daily as necessary for adverse reactions of myelosuppression, peripheral neuropathy, and optic neuropathy.
 - Doses of the regimen missed for safety reasons can be made up at the end of treatment; doses of linezolid alone missed due to adverse reactions should not be made up.

V. Dosage and Administration

Indication	Dosing Regimen	Maximum Dose
Drug resistant pulmonary TB	Administer in combination with bedaquiline and linezolid in a directly observed therapy (DOT) setting. - Pretomanid: 200 mg PO QD for 26 weeks*. - Sirturo: 400 mg PO QD for 2 weeks followed by 200 mg 3 times per week (at least 48 hours between doses) for the remaining 24 weeks (total duration of 26 weeks*). - Linezolid: 600 mg PO QD for 26 weeks*. Patients 17 years of age or older may continue treatment with Sirturo and pretomanid without linezolid if the patient has previously received a total daily dose of linezolid 1,200 mg for at least 4 weeks. <i>* Treatment with the BPAL regimen can be extended beyond 26 weeks up to 9 months (39 weeks) based on delayed treatment response within the first 8 weeks as assessed by time to culture conversion, persistent culture positivity, clinical response to treatment, and other underlying clinical factors, or modified based on adverse events.</i>	200 mg/day

VI. Product Availability

Tablets: 200 mg

VII. References

1. Pretomanid Prescribing Information. Hyderabad, India: Mylan; December 2022. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212862s000lbl.pdf. Accessed October 22, 2024.
2. ClinicalTrials.gov [Internet]. Identifier: NCT02333799, A Phase 3 Study Assessing the Safety and Efficacy of Bedaquiline Plus PA-824 Plus Linezolid in Subjects With Drug Resistant Pulmonary Tuberculosis. Available at: <https://clinicaltrials.gov/ct2/show/NCT02333799>. Accessed October 30, 2024.
3. Talwar A, Tsang CA, Price SF, et al. Tuberculosis — United States, 2018. MMWR Morb Mortal Wkly Rep 2019; 68(11):257–262.
4. WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: World Health Organization; 2019. License: CC BY-NC-SA 3.0 IGO. Available at: <https://apps.who.int/iris/bitstream/handle/10665/311389/9789241550529-eng.pdf>. Accessed October 30, 2024.
5. WHO Consolidated Guidelines on Tuberculosis, Module 4: Treatment - Drug-Resistant Tuberculosis Treatment. 15 June 2020. Available at: <https://www.who.int/publications/i/item/9789240007048>. Accessed October 30, 2024.
6. FDA Briefing Document for Pretomanid tablet, 200mg. Meeting of the Antimicrobial Drugs Advisory Committee (AMDAC): New York, NY: June 6, 2019. Available at: <https://public4.pagefreezer.com/content/FDA/31-05-2021T10:00/https://www.fda.gov/media/127593/download>. Accessed October 30, 2024.

7. Pretomanid: Sponsor Briefing Document Antimicrobial Drugs Advisory Committee. New York, NY: June 6, 2019. Available at: <https://public4.pagefreezer.com/content/FDA/31-05-2021T10:00/https://www.fda.gov/media/128001/download>. Accessed October 30, 2024.
8. Nahid P, Mase SR, Migliori GM, et al. Treatment of Drug-Resistant Tuberculosis: An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline. *Am J Respir Crit Care Med*. Nov 15, 2019. 200 (10): e93–e142.
9. Provisional CDC Guidance for the Use of Pretomanid as part of a Regimen [Bedaquiline, Pretomanid, and Linezolid (BPAL)] to Treat Drug-Resistant Tuberculosis Disease. Updated February 8, 2024. Available at: https://www.cdc.gov/tb/hcp/treatment/bpal.html?CDC_AAref_Val=https://www.cdc.gov/tb/topic/drtb/bpal/. Accessed October 30, 2024.
10. WHO-Rapid communication: Key changes to the treatment of drug-resistant tuberculosis. May 2022. Available at: <https://www.who.int/publications/i/item/WHO-UCN-TB-2022-2>. Accessed October 30, 2024.
11. Center for Disease Control and Prevention. Treating Drug-resistant Tuberculosis Disease. Updated May 6, 2024. Available at: https://www.cdc.gov/tb/treatment/drug-resistant-tuberculosis.html?CDC_AAref_Val=https://www.cdc.gov/tb/topic/drtb/default.htm. Accessed October 30, 2024.
12. WHO consolidated guidelines on tuberculosis: module 5: management of tuberculosis in children and adolescents. 18 March 2022. Available at: <https://www.who.int/publications/i/item/9789240046764>. Accessed October 30, 2024.
13. WHO-Key updates to the treatment of drug-resistant tuberculosis: rapid communication, June 2024. Available at: <https://www.who.int/publications/i/item/B09123>. Accessed October 30, 2024.

Reviews, Revisions, and Approvals	Date	P&T Approval Date
1Q 2021 annual review: no significant changes; references to HIM.PHAR.21 revised to HIM.PA.154; references reviewed and updated.	11.03.20	02.21
Clarified expert in the treatment of tuberculosis to include state or county public health department, specialists affiliated with any of the four TB Centers of Excellence as designated by the CDC, or ID specialists managing TB clinics.	02.17.21	05.21
1Q 2022 annual review: no significant changes; references reviewed and updated.	09.23.21	02.22
Template changes applied to other diagnoses/indications and continued therapy section.	10.06.22	
1Q 2023 annual review: lowered age requirement from 17 to 15 years per updated WHO 2022 guidance, clarified approval duration from 6 months to 26 weeks; for continued therapy reinforced therapy duration requirements that were previously only referenced in the approval duration; added alternative option if there is no documented fluoroquinolone resistance for off-label use when prescribed in combination with moxifloxacin; RT4: updated FDA	01.13.23	02.23

Reviews, Revisions, and Approvals	Date	P&T Approval Date
approved indication language, removed references to multidrug-resistant TB and extensively drug-resistant TB and replaced with drug regimens for drug resistance consistent with the updated prescribing information; references reviewed and updated.		
1Q 2024 annual review: no significant changes; updated linezolid dosing from 1,200 mg to 600 mg per updated CDC recommendations; references reviewed and updated.	10.20.23	02.24
1Q 2025 annual review: no significant changes; references reviewed and updated.	10.22.24	02.25

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions, and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment, or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to

recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members, and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note:

For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2019 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene[®] and Centene Corporation[®] are registered trademarks exclusively owned by Centene Corporation.